The Global Artificial Intelligence in Clinical Trials Market

Source Domain: www.openpr.com

Market Value and Growth Projection: The Artificial Intelligence (AI) in Clinical Trials market was valued at USD 1,350.79 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 12.04% to reach USD 3,334.47 million by 2032.
Key Developments: Significant advancements are noted such as Suvoda’s launch of Sofia, an AI-powered assistant to streamline clinical trial management in March 2025, and acquisition talks initiated by Avant Technologies, Inc. in May 2025.
Leading Companies: Prominent companies in the market include TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, and Research Solutions.
Regional Market Dominance: North America dominates the AI in Clinical Trials market in 2024, attributed to various key influencing factors.
Market Drivers: The rise is driven by the increasing global prevalence of chronic diseases and significant investments to advance drug discovery and development, coupled with strategic partnerships among pharmaceutical and medical device companies.

You may have missed